Objectives: This phase III trial asks whether third-line cabozantinib, a novel oral multi-targeted tyrosine kinase inhibitor, can improve overall survival compared with prednisone after treatment failures with leading approved and novel therapies.
Key entry or exclusion criteria: Patients must have received prior docetaxel (Taxotere) plus either abiraterone (Zytiga) or enzalutamide (Xtandi, MDV3100) treatment, and have evidence of prostate cancer progression on each agent independently.
Locations: 10 sites.
Goal: 960 patients.
Study sponsor: Exelixis
Link for more information: clinicaltrials.gov/ct2/show/NCT01605227
NIH clinical trials identifier: NCT01605227